Last reviewed · How we verify
NCT07356752: PLUTO
Prediction of Lung Transplant Outcome
NA trial testing Research Blood Sampling and Biocollection in Graft Dysfunction in 4,200 participants. Participants enrolled and being followed up; not accepting new ones.
1 June 2031
Quick facts
| Lead sponsor | Hopital Foch |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 4,200 |
| Start date | 17 June 2025 |
| Primary completion | 1 June 2031 |
| Estimated completion | 1 June 2031 |
| Sites | 9 locations across France |
Drugs / interventions tested
- Research Blood Sampling and Biocollection
Conditions studied
- Graft Dysfunction — all drugs for Graft Dysfunction →
- Lung Transplantation — all drugs for Lung Transplantation →
- Chronic Lung Allograft Dysfunction (CLAD) — all drugs for Chronic Lung Allograft Dysfunction (CLAD) →
- Chronic Rejection of Lung Transplant — all drugs for Chronic Rejection of Lung Transplant →
Sponsor
Hopital Foch — full company profile →
Who can join
Adults 15 to 100, any sex, with Graft Dysfunction or Lung Transplantation. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Discrimination Performance of the Multidimensional Dynamic Prognostic Model for Lung Graft Outcomes, Measured by Area Under the Curve (AUC)
Time frame: 72 months
To develop a multidimensional and dynamic prediction system for lung graft outcomes, joint multivariate Bayesian models with shared parameters and optimal artificial intelligence approaches will be used to assess associations between longitudinal biomarkers and survival data. This approach combines a Cox model linking time-to-event data with joint mixed models estimating trajectories of repeated m
Sponsor's own description
Plain Language Summary of the PLUTO Study Prediction of Lung Transplant Outcomes (PLUTO) What is this study about? This study aims to improve how doctors predict the health of lung transplant recipients over time. Many people with severe lung disease need a transplant, but even after receiving a new lung, some still face serious health issues. One of the biggest problems is chronic lung transplant dysfunction (CLAD), which can slowly damage the new lung and is currently irreversible. What is the goal of the study? Researchers want to better understand why some people do worse after a lung transplant. Researchers hope to identify early warning signs and improve diagnosis. The main goal is to build a model that can predict how well a lung transplant will function over time, using routine health data and test results from transplant patients. Who can take part in this study? People aged 15 and older who had a lung transplant between 2009 and 2027 and are being followed at one of the study centers. People who speak French and have national health insurance. People who gave written consent (or whose guardians did, if under 18). The study may also use past data from deceased patients who did not object to research use. How will the study work? The study will follow about 4,200 lung transplant recipients across many centers in France. Researchers will collect clinical data, lung function tests, biopsy results, and blood samples. Researchers will also study new biomarkers (signals in the body that may show how well a transplant is doing) found in blood or lung samples. Using these data, the investigators will build and test tools to predict transplant outcomes. Why is this research important? By understanding early signs of transplant problems, doctors can act sooner and tailor treatment for each person. This may improve long-term survival after a lung transplant and help guide future research. How long is the study? Each participant will be followed for about 3 years, and the full study will last 6 years, including data analysis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07356752
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Graft Dysfunction
Currently open trials in the same condition.
- NCT03786991 — EPI-STORM: Cytokine Storm in Organ Donors · recruiting
Other Hopital Foch trials
Trials by the same sponsor.
- NCT06980844 — Interpretation of the Role of Eosinophils in Diffuse Interstitial Pneumopathies · NA · not yet recruiting
- NCT06757244 — DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer · Phase 2 · recruiting
- NCT06631794 — Evaluation of the Impact of a HPV Vaccination Talk with Third Grade Students · not yet recruiting
- NCT06533436 — Clinical and Economic Comparison of 2 Methods of Intubation Tube Fixation : AnchorFastTM Versus Current Cord Fixation · NA · recruiting
- NCT06476002 — Analysis of the Understanding of the French Version of the Vulvar Pain Assessment Questionnaire · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07356752 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hopital Foch
- Last refreshed: 12 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07356752.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing